Mona Elmacken

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

Aradhana Awasthi, Janet Ayello, Carmella van de Ven et al. · British Journal of Haematology · 2015 · 89 citations · Full text

Obinutuzumab Versus Rituximab, Immunology, Cell Death +16

FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang et al. · Clinical Cancer Research · 2024 · 15 citations

Pharmacotherapy, Hematological Malignancy, Metronomic Therapy +19

Loss of Circulating Mucosal-Associated Invariant T Cells in Common Variable Immunodeficiency Is Associated with Immune Activation and Loss of Eomes and PLZF

Dominic Paquin‐Proulx, Bianca A. N. Santos, Nathália Silveira Barsotti et al. · ImmunoHorizons · 2017 · 10 citations · Full text

Immune Activation, Adaptive Immune System, Immunodeficiencies +24